PRME logo

PRIME MEDICINE INC

PRMENASDAQ
🏆 #2903 by market capEarnings Oct 30US Equity
$3.11▲ $0.24 (+7.81%)
Market closed · at close
🔔
Track PRME
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.8%
7d▼ 0.6%
14d▲ 3.2%
30d▼ 13.5%
ytd▼ 10.0%
1y▼ 43.9%
🏦Market Cap
$561M
Small Cap
📈Revenue Growth (YoY)
-17.9%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
137.6x
Expensive
Otter Score
44
Weak

Trading Snapshot

Day Range
$3.06 – $3.12
52-Week Range
$2.67 – $6.94
Volume
$4.00B
Avg Volume
$5.24B
Shares Outstanding
180.6M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
137.6x
EPS (TTM)
$-1.09
Dividend Yield
—
Dilution (1yr)
+25.4%

Why Investors Own PRME

  • ✓High-growth profile — revenue up -3.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRME logo

PRIME MEDICINE INC

PRME
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▲ +55.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-58.1%▼ −158.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$208M▲ +2.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$167M▲ +28.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
148.8M▲ +25.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$53M▼ −$195M YoY
StockOtter · stockotter.space

About PRIME MEDICINE INC

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$4.14
▲ +33.2% Upside
High Target$4.53
Low Target$3.68
Based on 32 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PRIME MEDICINE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift PRME price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

PRIME MEDICINE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.